Dr. Flinn Discusses the DYNAMO Trial

In Partnership With:

Partner | Cancer Centers | <b>Sarah Cannon Research Institute at Tennessee Oncology</b>

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Ian W. Flinn, MD, PhD, director, Hematologic Malignancies Research Program, Sarah Cannon Research Institute, discusses the DYNAMO Trial, which is looking at IPI-145 for the treatment of patients with refractory indolent non-Hodgkin lymphoma.

Flinn says this phase II trial enrolled patients who were no longer responding to rituximab or chemotherapy. There is currently no established therapy for these patients.

In this trial, all patients will receive IPI-145, an oral inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, as a single agent, Flinn says. Targeting PI3K-delta and PI3K-gamma may provide multiple opportunities to develop differentiated therapies for the treatment of blood cancers and inflammatory diseases.

The trial is ongoing and is currently accruing patients in the United States and the United Kingdom.